Streetbeat News

Price Targets

MKC

Citigroup analyst Thomas Palmer has maintained a Sell rating on McCormick & Co (NYSE:MKC) but raised the price target from $60 to $68.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 5:09 pm

CHX

Citigroup analyst Scott Gruber maintains a Buy rating on ChampionX (NASDAQ:CHX) and raises the price target from $39 to $40.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 5:07 pm

BKKT

Citigroup analyst Peter Christiansen has maintained a Sell rating on Bakkt Holdings (BKKT) and reduced the price target from $0.5 to $0.3.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 5:06 pm

NLY

Keefe, Bruyette & Woods analyst Bose George maintains an Outperform rating on Annaly Capital Management (NLY) with a price target of $21.5.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 5:02 pm

BOKF

Keefe, Bruyette & Woods analyst Wood Lay maintains a 'Market Perform' rating on BOK Financial (NASDAQ:BOKF) and keeps the price target at $94.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 5:00 pm

COF

Analyst reviews for Capital One Financial (COF) show diverse opinions, with recent updates indicating a mix of ratings from 'Neutral' to 'Buy'. The average 12-month price target for COF has increased to $143.43, reflecting a positive sentiment shift. Key financial indicators reveal a strong market presence and revenue growth, but challenges in ROE and ROA. Analyst actions, including rating adjustments and price target changes, highlight evolving market dynamics and company performance.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:00 pm

COF

Keefe, Bruyette & Woods analyst Sanjay Sakhrani maintains an Outperform rating on Capital One Financial (COF) with a price target of $159.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 4:58 pm

KROS

Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Keros Therapeutics (NASDAQ:KROS) with a price target of $105.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 4:48 pm

KRRO

Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on Korro Bio (NASDAQ:KRRO) and kept the price target at $180. This reaffirms the firm's positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 4:46 pm

GOSS

Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Gossamer Bio (GOSS) with a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 4:43 pm